FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
1,276 letters match. Newest first.
-
DrugsSanofi
FDA warned Sanofi subsidiary Genzyme over manufacturing quality failures at its Framingham, MA API plant.
High risk -
Drugswww.weightcrunchshop.com
FDA warned www.weightcrunchshop.com about selling unapproved and misbranded semaglutide and oxycodone drugs to U.S. consumers online.
High risk -
DrugsAtlanta Supersource, Inc.
Atlanta Supersource made OTC hand sanitizers on equipment shared with toxic industrial chemicals and lacked testing, FDA says.
High risk -
DrugsINCELL Corporation LLC
FDA warned INCELL Corporation for making an unapproved amniotic-fluid drug without validating its sterile manufacturing process.
High risk -
DrugsIndoco Remedies Limited
FDA warned Indoco Remedies over manufacturing quality failures at its Goa plant, including unreliable microbial testing and aseptic processing deficiencies.
High risk -
DrugsBhargava Phytolab Private Limited
FDA warns Bhargava Phytolab over drug and API current good manufacturing practice (CGMP) violations, including inadequate testing and sterility controls.
High risk -
DrugsViatris, Inc.
FDA warns Viatris that its Indore, India, drug plant had unreliable quality data and weak investigations.
High risk -
DrugsSombra Cosmetics, Inc.
FDA warned Sombra Cosmetics of OTC drug CGMP violations, including inadequate water controls and component testing.
High risk -
DrugsAkron Formulations India Private Limited
Akron Formulations India's over-the-counter drugs are adulterated due to manufacturing quality (CGMP) failures, including unqualified active ingredient (API) suppliers and inadequate microbial testing.
High risk -
DrugsBrands International Corporation
Brands International, a Canadian drug manufacturer, limited an FDA inspection and had manufacturing quality violations including mold contamination.
High risk -
DrugsPrime Vitality, Inc. dba Prime Peptides
FDA warned Prime Peptides that its website sells Semaglutide and Retatrutide as unapproved new drugs for weight loss and diabetes.
High risk -
DrugsSwisschems
Swisschems sells Semaglutide and Retatrutide as unapproved new drugs despite research-chemical labeling.
High risk -
DrugsXcel Research LLC
FDA warned Xcel Research for selling unapproved peptide drugs online with human-use claims.
High risk -
DrugsSummit Research Peptides
FDA warned Summit Research Peptides for selling unapproved semaglutide, retatrutide, cagrilintide, tirzepatide, and mazdutide with drug claims.
High risk -
DrugsVeronvy
FDA warned Veronvy that its Elily Veronvy weight-loss drops are unapproved new drugs and falsely labeled "FDA APPROVED."
Medium -
DrugsMicro Orgo Chem
Micro Orgo Chem in India failed CGMP for API drugs, including cleaning, process validation, stability and records.
High risk -
DrugsDr. Brite, LLC
FDA cited Dr. Brite for manufacturing quality failures and selling unapproved, misbranded oral care and hand sanitizer drugs.
High risk -
DrugsGuangzhou Four E’s Scientific Co., Ltd.
FDA warns Guangzhou Four E’s over CGMP failures for OTC drugs, including a sterile-labeled product with inadequate sterility assurance.
High risk -
DrugsHan C. Phan, M.D.
FDA warns clinical investigator Dr. Han C. Phan over failure to follow a drug study’s protocol for required tests.
Medium -
DrugsApplied Therapeutics, Inc.
Applied Therapeutics, a trial sponsor, failed to let FDA access deleted electronic trial data and omitted dosing-error information from its drug application.
High risk -
DrugsLCC Ltd.
FDA warned LCC Ltd. over manufacturing-quality failures, contamination testing gaps, discarded lab data, and unapproved mouthwash drugs.
High risk -
DrugsZhejiang Uniquality Nursing Products Technology Co., Ltd. dba ZheJiang YouQuan Care Products Technology Co., Ltd.
FDA warns Zhejiang Uniquality over inadequate OTC drug component testing and quality oversight; import alert issued.
High risk -
DrugsCatwalk Cosmetic Laboratories Pty Ltd.
FDA warns South African over-the-counter drug maker Catwalk Cosmetic Laboratories of current good manufacturing practice violations and import alert.
High risk -
DrugsEurosirel S.P.A
FDA warns Eurosirel over CGMP failures in topical drugs and pain patches, including missing glycerin identity testing.
High risk -
DrugsHangzhou Huiji Biotechnology Co., Ltd.
FDA warned Hangzhou Huiji Biotechnology over CGMP failures in OTC hand sanitizers, including missing glycerin and ethanol safety tests.
High risk -
DrugsCentura Pharmaceuticals Inc
FDA warned Centura Pharmaceuticals that its BLT 1-2-3 Cream, a mixed numbing product for cosmetic procedures, is an unapproved new drug.
High risk -
DrugsOriginitalia SRL
FDA warns Originitalia SRL over manufacturing quality failures in OTC drugs, including untested active ingredient and missing release testing.
High risk -
DrugsRichard W. Foltin, Ph.D.
FDA warned sponsor Dr. Richard W. Foltin for starting drug trials in people without an IND.
High risk -
DrugsUnexo Lifesciences, Private Limited
FDA warned Unexo Lifesciences over serious CGMP violations, including data integrity failures and torn batch records for U.S.-bound drugs.
High risk -
DrugsColgate-Palmolive/Tom's of Maine, Inc.
FDA cited Tom's of Maine for CGMP failures after finding objectionable microbes in water and toothpaste and inadequate complaint handling.
High risk -
DrugsTianjin Darentang Jingwanhong Pharmaceutical Co., Ltd.
FDA cited Tianjin Darentang Jingwanhong Pharmaceutical for limiting a drug inspection and manufacturing violations at its China plant.
High risk -
DrugsZhejiang Qimei Cosmetics Co., Ltd.
Zhejiang Qimei Cosmetics drew an FDA warning for CGMP violations in sterile-labeled OTC isopropyl alcohol prep pads.
High risk -
DrugsMultaler et Cie SAS
FDA cites Multaler et Cie for manufacturing failures and unapproved sunscreen after April 2024 inspection.
High risk -
DrugsArmstrong County Memorial Hospital
FDA warns Armstrong County Memorial Hospital review board over missing procedures and inadequate meeting minutes for drug research.
Medium -
DrugsFancy Drops Beauty LLC
FDA says Fancy Drops Beauty sells unapproved eye drops claimed to change eye color.
High risk -
DrugsAnalytical Food Laboratories, Inc.
FDA warned contract testing lab Analytical Food Laboratories after inspection found unvalidated drug test methods and weak quality oversight.
High risk -
DrugsMedOffice Saglik Endustri Anonim Sirketi
FDA warned MedOffice Saglik after an inspection found missing batch release testing and inadequate process validation for over-the-counter drugs.
High risk -
DrugsChoice All Natural, Inc. dba Om Botanical
FDA warns Om Botanical of Apex, NC over filthy manufacturing, an unapproved rash cream, and lapsed FDA registration.
High risk -
DrugsDiora Kimya Sanayi ve Ticaret Limited Sirketi
FDA cited Diora Kimya for drug manufacturing quality failures and for an unlisted antibacterial soap.
High risk -
DrugsSoliteint Kozmetikai KFT
Hungarian contract maker Soliteint Kozmetikai failed to test OTC pain-relief drugs and ingredients, FDA says; U.S. production halted.
High risk -
DrugsOmni Lens Pvt. Ltd.
FDA warns Omni Lens about CGMP failures and misbranding of ophthalmic OTC drugs made by unregistered contract manufacturers.
High risk -
DrugsStokes Healthcare Inc. dba Epicur Pharma
Sterile compounding facility Epicur Pharma made drugs under insanitary conditions and with serious quality failures, FDA says.
High risk -
DrugsOutin Futures Corp.
FDA warned Outin Futures, a Korean drug manufacturer, of CGMP violations and sunscreen misbranding after a March 2024 inspection.
High risk -
DrugsMexicanrxpharm.com
FDA told Mexicanrxpharm.com to stop selling unapproved, misbranded opioid pain drugs to U.S. consumers online.
High risk -
DrugsLouisiana State University Health Science Center IRB
FDA warns Louisiana State University Health Science Center IRB about missed continuing reviews and unreported study terminations for drug research.
Medium -
DrugsMMC Healthcare Ltd.
FDA warned MMC Healthcare Ltd. in Chennai that its drug products violate manufacturing rules, citing backdated records, weak computer controls, and unvalidated test methods.
High risk -
DrugsSupercore Products Group, Inc.
FDA warns Supercore that Hard Steel and Gold Hard Steel Plus are unapproved, mislabeled drugs with hidden sildenafil; Hard Steel also has acetaminophen.
High risk -
DrugsMakra Kozmetika D.O.O.
FDA warns Makra Kozmetika over OTC drug manufacturing violations, including missing batch and ingredient testing, after April 2024 inspection.
High risk -
DrugsLittle Moon Essentials, LLC
FDA warns Little Moon Essentials over CGMP failures and unapproved topical analgesic drugs made in Dania Beach, Florida.
High risk -
DrugsDiamond Chemical Co., Inc.
Diamond Chemical Co. in East Rutherford, NJ, made OTC hand sanitizers without required ingredient and finished-product testing or process validation.
High risk